Crossmark

MHC class I and II-deficient humanized mice are suitable tools to test the long-term antitumor efficacy of immune checkpoint inhibitors and T-cell engagers

Crossref DOI link: https://doi.org/10.1136/jitc-2023-008516

Published Online: 2024-09-06

Published Print: 2024-09

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Eguren-Santamaria, Iñaki https://orcid.org/0000-0003-1581-3728
Fernández de Piérola, Eva

Camps, Gracián

Martín-Muñoz, Paula

Campos, María

Cuculescu, Doina

Aguilera-Buenosvinos, Inmaculada

Rodríguez López, Inmaculada

Salido-Vallejo, Rafael

Alexandru, Raluca

De Andrea, Carlos E

Álvarez-Gigli, Laura

Berraondo, Pedro https://orcid.org/0000-0001-7410-1865
Melero, Ignacio https://orcid.org/0000-0002-1360-348X
Sanmamed, Miguel F
Funding

Funding for this research was provided by:

CRIS Cancer Foundation (PR_EX_22-36)

Instituto de Salud Carlos III (ISCIII PI19/00668)

Fundación Científica Asociación Española Contra el Cáncer (CLJUN20011EGUR, LABAE211756FERN)

Spanish Ministry of Science and Innovation (PID:2020-112892RB)

Mark Foundation For Cancer Research (ASPIRE Award)

Fundació Marató de TV3 (488/C/2019)

Fundación Fero (BBASELGAFERO2022-01)

Instituto de Salud Carlos III/Fondo Europeo de Desarrollo Regional (PI21/01547[CEDA])
License Information

License valid from 2024-09-06

Document is current

Any future updates will be listed below